Selected article for: "body temperature and maximum body temperature"

Author: Gao, Wei; Chen, Si; Wang, Kun; Chen, Rongzhang; Guo, Qian; Lu, Jingjing; Wu, Xiaodong; He, Yanan; Yan, Qiaoyun; Wang, Shengyun; Wang, Feilong; Jin, Li; Hua, Jing; Li, Qiang
Title: Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series
  • Cord-id: py0bxuk3
  • Document date: 2020_10_23
  • ID: py0bxuk3
    Snippet: OBJECTIVE: We aimed to describe the features of 220 nonemergency (mild or common type) COVID-19 patients from a shelter hospital, as well as evaluate the efficiency of antiviral drug, Arbidol in their disease progressions. METHODS: Basic clinical characteristics were described and the efficacy of Arbidol was evaluated based on gender, age, maximum body temperature of the patients. RESULTS: Basically, males had a higher risk of fever and more onset symptoms than females. Arbidol could accelerate
    Document: OBJECTIVE: We aimed to describe the features of 220 nonemergency (mild or common type) COVID-19 patients from a shelter hospital, as well as evaluate the efficiency of antiviral drug, Arbidol in their disease progressions. METHODS: Basic clinical characteristics were described and the efficacy of Arbidol was evaluated based on gender, age, maximum body temperature of the patients. RESULTS: Basically, males had a higher risk of fever and more onset symptoms than females. Arbidol could accelerate fever recovery and viral clearance in respiratory specimens, particularly in males. Arbidol also contributed to shorter hospital stay without obvious adverse reactions. CONCLUSIONS: In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient's conditions. Arbidol showed several beneficial effects in these patients, especially in males. This study brought more researches enlightenment in understanding the emerging infectious disease.

    Search related documents:
    Co phrase search for related documents
    • acid assay and additional file: 1
    • acid detection and acute respiratory infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acid detection and additional file: 1
    • acid detection and lopinavir ritonavir: 1, 2, 3
    • acid negative conversion time and acute respiratory infection: 1
    • acid negative conversion time and additional file: 1
    • acid negative conversion time and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
    • acute respiratory infection and additional file: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory infection and long protect: 1
    • acute respiratory infection and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • additional file and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • lopinavir ritonavir and low grade fever: 1, 2